Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ju Fu Tang Biotech Holdings Co's earnings before interest and taxes (EBIT) for the
six
months ended in Mar. 2026 was HK$2.24 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was HK$24.04 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Ju Fu Tang Biotech Holdings Co's annualizedROC % for the quarter that ended in Mar. 2026 was -64.71%.
Ju Fu Tang Biotech Holdings Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7,401.65%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Ju Fu Tang Biotech Holdings Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -144.33%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ju Fu Tang Biotech Holdings Co EBIT Related Terms
Ju Fu Tang Biotech Holdings Co EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Engineering & Construction subindustry, Ju Fu Tang Biotech Holdings Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ju Fu Tang Biotech Holdings Co EV-to-EBIT vs Construction Industry
For the Construction industry and Industrials sector, Ju Fu Tang Biotech Holdings Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ju Fu Tang Biotech Holdings Co's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$24.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ju Fu Tang Biotech Holdings Co (HKSE:08217) has a EBIT of HK$24.04 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ju Fu Tang Biotech Holdings Co.
Is Ju Fu Tang Biotech Holdings Co's EBIT too high?
Ju Fu Tang Biotech Holdings Co's current EBIT is HK$24.04 Mil. Overall, Ju Fu Tang Biotech Holdings Co has a GF Score™ of 36/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ju Fu Tang Biotech Holdings Co's EBIT compare to PWR and FIX?
Ju Fu Tang Biotech Holdings Co's EBIT of HK$24.04 Mil can be compared against companies in the Construction industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Construction company?
A good EBIT depends on the Construction industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ju Fu Tang Biotech Holdings Co. Ju Fu Tang Biotech Holdings Co's current EBIT is HK$24.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ju Fu Tang Biotech Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Ju Fu Tang Biotech Holdings Co (HKSE:08217) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.15, compared to a current price of HK$0.11 — trading 28.7% below its estimated fair value. The current EBIT is HK$24.04 Mil. Ju Fu Tang Biotech Holdings Co's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Ju Fu Tang Biotech Holdings Co (HKSE:08217), the current EBIT is HK$24.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ju Fu Tang Biotech Holdings Co (HKSE:08217) Overvalued in 2026?
Based on GuruFocus' analysis, Ju Fu Tang Biotech Holdings Co stock appears to be undervalued.
The current stock price of HK$0.11 is trading 28.7% below its estimated GF Value™ of HK$0.15.
GuruFocus considers Ju Fu Tang Biotech Holdings Co to be Modestly Undervalued.
Key valuation signals for HKSE:08217:
EBIT: HK$24.04 Mil
GF Value™: HK$0.15 vs. price of HK$0.11 (28.7% below fair value)
No single metric tells the full story. See the HKSE:08217 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ju Fu Tang Biotech Holdings Co Ltd, formerly known as WMHW Holdings Ltd, is an investment holding company operating through its subsidiaries. It engaged in the provision of construction works and investment holding.
36GF Score
Get the complete analysis for HKSE:08217
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08217 has been successfully added to your 
